ArticleProceedings (Baylor University. Medical Center)
Unmasking the risk: euglycemic diabetic ketoacidosis induced by GLP-1 agonist in type 2 diabetes.
Article in Proceedings (Baylor University. Medical Center). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report.International medical case reports journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Euglycemic diabetic ketoacidosis (EDKA) is a rare but serious complication of type 2 diabetes, traditionally linked to SGLT-2 inhibitors. We report a 59-year-old woman with type 2 diabetes and gastroparesis who discontinued SGLT-2 inhibitors 1 month earlier and developed EDKA shortly after initiating dulaglutide. She presented with nausea, vomiting, abdominal pain, and a modestly elevated glucose level. Laboratory findings confirmed EDKA, and she was successfully treated with intravenous insulin and fluids. Dulaglutide was discontinued, with no recurrence on follow-up. This case underscores the potential for GLP-1 receptor agonists to trigger EDKA in susceptible patients and the need for heightened clinical awareness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.